In a randomized , open-label , single-center trial , recipients of renal transplants ( recipient or donor cytomegalovirus-seropositive ) were randomly allocated ( 1:1 ) to 3-month prophylaxis with valacyclovir ( 2 g four times daily ) or valganciclovir ( 900 mg daily ) .